Loading...

KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC Expansion Plans 8-K Filing

KNKS

KNS

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

(KNSA)

2025 8-K

Financial Results Announced

Investor Presentation Update

Financial Statements

Product Expansion

Management Changes

Product Expansion

License Termination

Financial Results

Q3 Earnings Report

Board Appointment

Earnings Reports

Agreement with Samsung Biol...

Redomiciliation

Annual Meeting and Special ...

Earnings Reports

Redomiciliation Proposal

Earnings Reports

Financial Results

Earnings Reports

Earnings Releases

Annual Meeting of Shareholders

Earnings Reports

Regulation FD Disclosure

Earnings Reports

Financial Results Announcement

External Links:

On June 5, 2025, Kiniksa Pharmaceuticals announced that their KPL-387 Phase 2/3 clinical trial for recurrent pericarditis is set to start in mid-2025, with Phase 2 results anticipated in the second half of 2026. An investor presentation was also made available on their website.

AI Assistant

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.